Cure SMA to Host Webinar on Spinraza Access, as List of Administration Sites is Released

Leave a Comment / Community Awareness, Front Page News /

On Thursday, May 4, at 1:00pm EST (10:00am PST/11:00am MST/12:00pm CST), Cure SMA will hold a webinar updating the community on the status of Spinraza access. Among the topics covered will be: The current status of dosing in states across the US Administration sites, including information on the recent launch of our site list Commercial […]

Cure SMA to Host Webinar on Spinraza Access, as List of Administration Sites is Released Read More »

The European Medicines Agency (EMA) Recommends Granting Marketing Authorization in the European Union for Spinraza

Leave a Comment / Front Page News /

The European Medicines Agency (EMA) has recommended granting a marketing authorization in the European Union (EU) for Spinraza. The recommendation indicates that Spinraza should be covered for all types of SMA. This recommendation is the first step in a three-step process to bring Spinraza to European patients. Next, the EMA’s recommendation will go to the

The European Medicines Agency (EMA) Recommends Granting Marketing Authorization in the European Union for Spinraza Read More »

Cure SMA Awards $75,000 Grant to Jean Giacomotto, PhD, University of Queensland, Australia

Leave a Comment / Front Page News, Research /

Cure SMA has awarded a $75,000 research grant to Jean Giacomotto, PhD, at the University of Queensland, for his project, “Zebrafish models of Spinal Muscular Atrophy optimized for chemical genetics and drug discovery. From proof-of-principle to new insights and treatments”. In SMA, the lack of additional “druggable” targets, beyond SMN, creates a gap in the

Cure SMA Awards $75,000 Grant to Jean Giacomotto, PhD, University of Queensland, Australia Read More »

Cure SMA Publishes Second Journal Article on the Patient Voice

Leave a Comment / Community Awareness, Front Page News /

Cure SMA, along with collaborators from Biogen and the SMA Foundation, have published a paper in the journal BMC Neurology.  In recent years, we’ve completed 16 focus group sessions and 37 interviews in the US with 96 participants including: 21 with individuals with SMA; 64 parents of individuals affected by SMA; and 11 clinicians who

Cure SMA Publishes Second Journal Article on the Patient Voice Read More »

Cure SMA Awards $30,000 Grant to Remy Bordonne, PhD, CNRS-Centre National de Recherche Scientifique, France

Leave a Comment / Front Page News, Research /

Cure SMA has awarded a $30,000 research grant to Remy Bordonne, PhD, at CNRS-Centre National de Recherche Scientifique, for his project, “Identification of the protective mechanism of a SMN modifier gene using S. pombe as a model organism”. In SMA, actin, which is a protein that helps muscles to contract, doesn’t work properly. The goal

Cure SMA Awards $30,000 Grant to Remy Bordonne, PhD, CNRS-Centre National de Recherche Scientifique, France Read More »

Cure SMA Receives Generous Donations from Fighting for Kaiden Foundation

Leave a Comment / Front Page News, Support & Care /

Cure SMA would like to thank the Fighting for Kaiden Foundation for their generous donations to our equipment pool and research programs. The foundation’s generosity will provide support and hope to all those effected by SMA.  The foundation recently donated two large size 2 EASyS strollers, one small size 1 EASyS stroller, and two large

Cure SMA Receives Generous Donations from Fighting for Kaiden Foundation Read More »

Record Number of Abstracts Submitted for the 2017 SMA Researcher Meeting

Leave a Comment / Conference, Front Page News, Research /

Abstract submission is now closed for the 2017 SMA Researcher Meeting. We are excited to announce that we received 125 submissions, a record number. Our submissions come from researchers in 14 countries, 10 companies, and close to 50 institutions. We expect over 300 researchers and clinicians from almost 100 organizations will attend the SMA Researcher

Record Number of Abstracts Submitted for the 2017 SMA Researcher Meeting Read More »

Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients with SMA

Leave a Comment / Clinical Trials, Front Page News /

Cytokinetics, Inc. today announced that the second cohort of the Phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA), is open to enrollment. This clinical trial is designed to assess the effect of CK-2127107, a next-generation fast skeletal troponin activator (FSTA), on multiple measures of muscle function in both ambulatory and

Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients with SMA Read More »

Cure SMA Coverage and Payment Policy Project Continues to Move Forward

Leave a Comment / Advocacy, Front Page News /

The Cure SMA Coverage and Payment Policy Project has two distinct but complementary tracks: Outreach on behalf of our community. We’re working with public and private insurers, regulators, and other stakeholders, advocating for prompt, comprehensive coverage for SMA treatments and care.  Outreach to our community. We’re working to provide the necessary tools and information so

Cure SMA Coverage and Payment Policy Project Continues to Move Forward Read More »

Genentech Roche Releases Community Letter with Clinical Trial Updates

Leave a Comment / Clinical Trials, Front Page News /

Genentech Roche provided the following community statement with clinical trial updates for SUNFISH (Type 2/3), FIREFISH (Type 1) and JEWELFISH. Dear SMA community, At Genentech (A Member of the Roche Group) we are committed to addressing the urgent needs of people living with SMA. We are happy to share this update on our two investigational

Genentech Roche Releases Community Letter with Clinical Trial Updates Read More »

Scroll to Top